Document Detail


Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
MedLine Citation:
PMID:  20234784     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The prevalence of AF increases sharply in old age (prevalence approximately 10% among persons 80 years of age and older). The expected risk for ischemic stroke is increased five-fold by the presence of AF, primarily as a result of cardiogenic embolism. Multiple large-scale, randomized trials have been completed or are still underway to find optimal, efficacious, and relatively safe ways to reduce the risk of ischemic stroke and other systemic thromboembolic events related to AF. Antithrombotic strategies are accompanied by serious bleeding complications that threaten patients in need of medical stroke prevention. Treatment regimens for preventing thromboembolism in AF patients range from vitamin K antagonists such as warfarin or coumadins, antiplatelet drugs like aspirin or clopidogrel, to newly developed orally available antithrombotics like the direct thrombin inhibitor dabigatran, or the Factor Xa-inhibitor rivaroxaban. The available anticoagulant and antiplatelet drugs have different advantages and disadvantages. This review attempts to delineate the specific role of clopidogrel in patients with AF and at risk of stroke, taking into consideration new and ongoing trials in this important field of medical practice.
Authors:
Lars Maegdefessel; Junya Azuma; Philip S Tsao
Related Documents :
18488074 - The use of antithrombotics in patients presenting with stroke and atrial fibrillation.
3477344 - Stuttering prevalence among patients at risk for velopharyngeal inadequacy: a prelimina...
11319974 - Effect of highly active antiretroviral therapy on cytomegalovirus antigenaemia in aids ...
8884824 - Effects of compliance with fluoride gel application on caries and caries risk in patien...
2884554 - Beta-blockers: a new therapeutic approach to raynaud's disease.
3489204 - Left hemisphere intracerebral hemorrhages studied by ( (f-18)-fluorodeoxyglucose pet.
Publication Detail:
Type:  Journal Article; Review     Date:  2010-03-03
Journal Detail:
Title:  Vascular health and risk management     Volume:  6     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2010  
Date Detail:
Created Date:  2010-03-17     Completed Date:  2011-01-27     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  95-103     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, School of Medicine, Stanford University, CA 94305-5406, USA. maegdefessel@stanford.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Atrial Fibrillation / complications*
Female
Hemorrhage / chemically induced
Humans
Male
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Stroke / etiology,  prevention & control*
Ticlopidine / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 55142-85-3/Ticlopidine; A74586SNO7/clopidogrel
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients i...
Next Document:  New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids.